PPIB and metabolic dysfunction-associated steatohepatitis: Comparing the data from both cyclophilin KO mouse lines relative to their respective controls, it is clear that only mice deficient in CypB had improved outcomes in terms of the most commonly used criteria for diagnosing NAFLD/NASH in humans.